Антифосфолипидный синдром - часть 35

145

30. Cheng Y, Austin SC, Rocca B, et al. Role of

prostacyclin in the cardiovascular response to
thromboxane A2. Science 2002; 296: 539—541.

31. Sadoshima J. Cytokine action of

angiotensin II. Circ Res 2000; 86: 1187—1189.

32. Brasier AR, Recinos A III, Eledsiri MS.

Vascular inflammation and the rennin
angiotensin system. Arterioscler Thromb Vasc Biol
2002; 22: 1257—1266.

33. Suzuki Y, RuizOrtega M, GomezGuerrero

C, et al. Angiotensin II, the immune system and
renal disease: another road for RAS? Nephrol
Dial Transplant 2—3; 18: 1423—1426.

34. Suzuki Y, RuizOrtega M, Lorenzo O, et al.

Inflammation and angiotensin II. Int J Biochem
Cell Biol 2003; 35: 881—900.

35. Luft FC. Angiotensin II, the AT2 receptor,

and nuclear factorkB activation. Kidney Int
2002; 61: 2272—2273.

36. RuizOrtega M. Lorenzo O, Ruperez M, et

al. Angiotensin II activates nuclear transcription
factor kB through AT1 and AT2 in vascular
smooth muscle cells: molecular mechanisms. Circ
Res 2000; 86: 1266—1272.

37. Wulf D. Free radicals in the Physiological

Control of Cell Function. Physiol Rew 2002; 82 :
47—95.

38. Nedelikovic ZS, Gokce N, Loscalzo J.

Mechanisms of oxidative stress and vascular dys
function. Postgrad Med J 2003; 79: 195—200.

39. Halliwell B, Gutteridge JMC. Free radicals

in biology and medicine (third edition), 2000;
Oxford University Press.

40. Welch GN, Koscalzo J. Homocystein and

atherothrombosis. N Engl J Med 1998; 338:
1042—1050.

41. The homocystein studies collaboration.

Homocystein and risk of ischemic heart disease
and stroke: a metaanalysis. JAMA 2002; 288:
2015—2022.

42. Cavalca V, Cighetti G, Bamonti F, et al.

Oxidative stress and homocystein in coronary
artery disease. Clin Chemistry 2001; 47: 887—
892.

43. Key NS, McGlennen RC. Hyperhomo

cysteinemia and thrombophilia. Arch Pathol Lab
Med 2002; 126: 1367—1375.

44. Ungvari Z, Csiszar A, Edwards JG, et al.

Increased superoxide production in coronart

arteries in hyperhomocysteinemia. Role of tumor
necrosis factor

α, NAD(P)H oxidase, abd

inducible nitric oxide synthase. Atheroscl.
Thromb Vasc Biol 2003; 23: 418—424.

45. Glass CK, Witztum JL. Atherosclerosis: the

road ahead. Cell 2001; 104: 503—516.

46. Barter P. Effects of inflammation on high

density lipoproteins. Arteriol Thromb Vasc Biol
2002; 22:1062—1064.

47. Navab M, Berliner JA, Subbanagounder G,

et al. HDL and inflammatory response induced by
LDLderived oxidized phospholipids. Arteriol
Thromb Vasc Biol 2001; 21: 481—488.

48. Hansen GK. Immune mechanisms in ather

osclerosis. Arterioscler Thromm Vasc Biol 2001;
21: 1876—1890.

49. Van der Thusen JH, Kuiper J, van Berrel

TJC, Biessen EAI. Interleukins in atherosclero
sis: molecular pathways and therapeutic poten
tial. Pharmacology Rev 2003; 55: 133—166.

50. Medzhotov R, Janeway C. Innate

Immunity. N Engl J Med 2000; 343: 338—344.

51. Kiechl S, Lorenz E, Reindl M, et al. Toll

like receptor 4 polymorphism and atherogenesis.
New Engl J Med 2002; 347: 185—192. 

52. Daugherty A, Rateri D. T lymphocytes in

atherosclerosis. The YinYang of Th1 and Th2
influence on ledion formation Circ Res 2002; 90:
1039—1040.

53. Prescott SM, McIntyre TM, Zimmerman

GA, Stafforini DM. Sol Sherry lecture in throm
bosis. Molecular events in acute inflammation.
Arterioscler Thromb Vasc Biol 2002; 22: 727—
733.

54. Warne JP. Tumor necrosis factor a: a key

regulator of adipose tissue mass J Endocrinol
2003; 377: 351—355.

55. Bazzoni F., Beutler B. Tumor necrosis fac

tor ligand and receptor families. N. Engl. J. Med.,
1996; 334:1717—1725.

56. Zhang M, Tracey KJ. Tumor necrоsis factor.

In: Thompson AW, er. The cytokine handbook, 3

rd

ed. New York. Academic press, 1998; 515—548.

57. Dinarello CA, Moldawer LL. Proinflam

matory and antiinflammatory cytokines in
rheumatoid arthritis. A primar for clinicians. Third
edition. 2002; Amgen Inc. 351 p.

58. Schreyer SA, Peschon JJ, LeBoeuf RC.

Accelerated atherosclerosis in mice lacking tumor

ГЛАВА 6. Иммунные механизмы атеросклероза

Насонов Е.Л. Антифосфолипидный синдром

146

necrosis factor receptor p55. J Biol Chem. 1996;
271: 26174—26178.

59. Zimmerman M, Selzman C, Reznikov LL,

et al. Lack of TNF

α attenuates untimal hyper

plasia after mouse carotide artery injury. Am J
Physiol Reg Integrat Comp Physiol 2002; 283:
R505—R512.

60. Ridker PM, Rifai N, Pfefer M, et al.

Elevation of tumor necrosis factor

α and

increased risk of recurrent coronary events after
myocardial infarction. Circulation 2000; 101:
2149—2153.

61. Elkind MS, Cheng J, BodenAlbata B., et

al. Tumor necrosis factor levels are associated
with carotid atherosclerosis. Stroke 2002; 33:
31—38.

62. Thrift AG. Association between tumor

necrosis factor receptor levels and carotide ather
osclerosis: is the association limited to younger
individuals? Stroke 2002; 33: 37—38

63. Blann AD, McCollum CN. Increased levels of

tumor necrosis factor receptors in atherosclerosis: no
clear relationship with levels of tumor necrosis fac
tor. Inflammation 22: 483—491. 

64. Chia S, Qadan M, Newton R, et al. Intra

arterial tumor necrosis factor

α impairs endotheli

umdependent vasodilatation and stimulates local
tissue plasminogen activator release in humans
Arteriol Thromb Vascular Biol 2003; 23: 659—665.

65. Hurlimann D, Forster A, Noll G, et al. Anti

tumor necrosis factor

α treatment improves

endothelial function in patients with rheumatoid
arthritis. Circulation 2002; 106: 2184—2187.

66. Zhou X, Paulsson G, Stemme S, Hansson

GK. Hypercholesterolemia is associated with a
Th1/Th2 switch of the autoimmune response in
atherosclerotic apo Eknockout mice. J Clin
Invest 1998; 101: 1717—1725.

67. Mallat Z, Besnard S, Duriez M, Deleuze V,

Emmanuel F, Bureau MF, Soubrier F, Esposito B,
Duez H, Fievet C, Staels B, Duverger N, Scherman
D, Tedgui A. Protective role of interleukin10 in
atherosclerosis. Circ Res 1999; 85: 17—24.

68. Terkeltaub R, Boisvert WA, Curtiss LK.

Chemokines and atherosclerosis. Curr Opin
Lipidol 1998; 9: 397—405.

69. Schonbeck U, Libby P. CD40 signaling and

plaque instability. Circulation Res 2001; 89:
1092—1103.

70. Andre P, NannizziAlaimp L, Prasard SK,

Philips DR. Plateletderived CD40L. The switch
hitting player of cardiovascular disease.
Circulation 2002; 106: 896—899. 

71. Vaarala O. Immunology of atherosclerosis.

In Vascular manifestations of systemic autoim
mune disease. Ed, RA Asherson, R Cervera. CRC
2002; 61—70.

72. Lozarda C, Levine RI, Hui M, et al.

Identification on C1q as the heartstable serum
cofactor required for immune complexes to stimu
late endothelial expression of the adhesion mole
cules Eselectin and intercellular and vascular
cell adhesion molecules I. Proc Natl Acad Sci
USA 1995; 92: 8378—8382.

73. Reiss AB, Malhotra S, Javitt NB, et al.

Occupancy of C1q receptors on endothelial cells
by immune complexes downregulates mRNA for
sterol 27hydroxylase; the major mediator of
extrahepatic cholesterol metabolism. Arthritis
Rheum 1998; (Suppl 9): A281.

74. Niculescu F, Rus HG, Vlaicu R. Activation

of the human terminal complement pathway in
atherosclerosis. Clin Immunol Immunopathol
1987; 45: 147—155.

75. Buono C, Come CE, Witztum JL, et al.

Influence of C3 deficiency on atherosclerosis.
Circulation 2002; 105: 3025—3031.

76. Gewurz H, Zhang XH, Lint TF. Structure

and function of the pentraxins. Curr Opin
Immunol 1995; 7: 54—64.

77. Pypes MB, Hirschfield GM. Creactive pro

tein: a critical update. J Clin Invest 2003; 111:
1805—1812.

78. Reynolds GD, Vance RP. Creactive protein

immunohistologically localisation in normal and
atherosclerotic human aorta. Arch Pathol Lab
Med 1987; 111: 265—269.

79. Torzewski J, Torzewski M, Bowyer D, et al.

Creactive protein frequently colocalizes with the
terminal complement complex in the intima of
early atherosclerotic lesions of human coronary
arteries. Arterioscl Thromb Vasc Biol 1998;
18:1386—1393.

80. Lagrand WK, Niessen HWM., Wolbink

GJ, et al. Creactive protein colocalizes with
complement in human heart during acute
myocardial infarction. Circulation 1997; 95:
97—103.

147

81. Wolbink GJ, Brouwer MC, Buysmann S, et

al. CRPmediated activation of complement in
vitro. J Immunol 1996; 157: 473—470.

82. Mold C, Gerwuz H, Du Clos TW. Regulation

of complement activation by Creactive protein.
Immunopharmacology 1999; 42: 23—30.

83. Nakajima T, Schulte S, Warrington KJ, et

al. Tcellmediated lysis of endothelial cells in
acute coronary syndrome. Circulation 2002; 105:
570—575.

84. Cermak J, Key N, Bach R, et al. Creactive

protein induces human peripheral blood monocyte
to synthesize tissue factor. Blood 1993; 82: 513—
520.

85. Nakagomi A, Freeedman SB, Geczy CL.

Interferon

γ and lipopolysaccharide potentiate

monocyte tissue factor induction by Creactive
protein. Relationship with age, sex, and hormone
replacement treatment. Circulation 2000;
101:1785—1791.

86. Torzewski M, Rist C, Mortensen RF, et al.

Creactive protein in the arterial intima. Role
of Creactive protein receptordependent
monocyte recruitment in the atherogenesis.
Arterioscl. Thromb Vasc Biol 2000; 20: 2094—
2099.

87. Pasceri V, Willerson JT, Yeh ETH. Direct

proinflammatory effect of Creactive protein on
human endothelial cells. Circulation 2000; 102:
2165—2168.

88. Zwaka TP, Hombach V, Torzewski J. C

reactive proteinmediated low density lipoprothein
uptake by macrophages. Circulation 2001; 103:
1194—1197.

89. Verma S, Wang CH, Li SH, et al. A self

fulfilling propenecy: Creactive protein attenu
ates nitric oxide production and inhibits angio
genesis. Circulation 2002; 106: 913—919

90. Venugopal SK, Devaraj S, Yuhanna I, et al.

Demonstration that Creactive protein decreases
eNOS expression and bioactivity in human aortic
endothelial cells. Circulation 2002; 106: 1439—1441. 

91. Devaraj S, Xu DY, Jialal I. Creactive pro

tein increases plasminogen activator inhibitor1
expression and activity in human aortic endothe
lial cells: implication for the metabolic syndrome
and atherothrombosis. Circulation 2003; 107:
398—404.

92. Danenberg HD, Szalai AJ, Swaminathan

RV, et al. Increased thrombosis after arterial
injury in human Creactive protein transgenic
mice. Circulation 2003; 108: 512.

ГЛАВА 6. Иммунные механизмы атеросклероза

В основе сосудистой патологии при АФС лежит невоспалительная

тромботическая васкулопатия, затрагивающая сосуды любого калибра и

локализации — от капилляров до крупных сосудов (включая аорту). По

этому спектр клинических проявлений АФС чрезвычайно разнообразен

1

.

В картине АФС могут преобладать венозные тромбозы или инсульты; аку

шерская патология, тромбоцитопения

7

или острая рецидивирующая коа

гулопатия и васкулопатия, сходная по течению с ДВС

молитико

ческого" АФС

8

.

Самыми частыми и характерными проявлениями АФС являются ве

нозные и/или артериальные тромбозы (развиваются примерно у трети

пациентов, в сыворотке которых выявлены аФЛ)

9

и акушерская патоло

гия. Это нашло свое отражение в международных предварительных клас

сификационных критериях АФС (глава 9).

Хотя характеристике клинических проявлений АФС посвящено

очень большое число исследований, истинная их распространенность до

последнего времени оставалась неизвестной. Это было в первую очередь

связано с относительно небольшим числом наблюдений в каждом кли

ническом центре. Кроме того, оставалось неясным, влияют ли на спектр

148

глава 7

К

К Л

Л И

И Н

Н И

И Ч

Ч Е

Е С

С К

К И

И Е

Е    П

П Р

Р О

О Я

Я В

В Л

Л Е

Е Н

Н И

И Я

Я   

А

А Н

Н Т

Т И

И Ф

Ф О

О С

С Ф

Ф О

О Л

Л И

И П

П И

И Д

Д Н

Н О

О Г

Г О

О   

С

С И

И Н

Н Д

Д Р

Р О

О М

М А

А